

DESCRIPTION


Specificity	Detects TGF-β3 in direct ELISAs and Western blots. In direct ELISAs and Western blots, less than 10% cross-reactivity with recombinant amphibian TGF-β5 is observed and less than 5% cross-reactivity with recombinant human (rh) TGF-β1, rhTGF-β2 and rhLAP (TGF-β1) is observed.
Source	Polyclonal Goat IgG
Purification	Protein A or G purified
Immunogen	<i>S. frugiperda</i> insect ovarian cell line Sf 21-derived recombinant chicken TGF-β3 and recombinant human TGF-β3 Ala301-Ser412 (Tyr340Phe) Accession # P10600
Endotoxin Level	<0.10 EU per 1 µg of the antibody by the LAL method.
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

	Recommended Concentration	Sample
Western Blot	1 µg/mL	Recombinant Human TGF-β3 (Catalog # 243-B3)
Neutralization	Measured by its ability to neutralize TGF-β3 inhibition of IL-4-dependent proliferation in the HT-2 mouse T cell line. Tsang, M. <i>et al.</i> (1995) Cytokine 7:389. The Neutralization Dose (ND ₅₀) is typically 1-3 µg/mL in the presence of 0.1 ng/mL Recombinant Human TGF-β3 and 7.5 ng/mL Recombinant Mouse IL-4.	

DATA



PREPARATION AND STORAGE

Reconstitution	Reconstitute at 1 mg/mL in sterile PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none"> ● 12 months from date of receipt, -20 to -70 °C as supplied. ● 1 month, 2 to 8 °C under sterile conditions after reconstitution. ● 6 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

TGF-β3 (transforming growth factor beta 3) is one of three closely related mammalian members of the large TGF-β superfamily that share a characteristic cystine knot structure (1–7). TGF-β1, -2 and -3 are highly pleiotropic cytokines that are proposed to act as cellular switches that regulate processes such as immune function, proliferation and epithelial-mesenchymal transition (1–4). Each TGF-β isoform has some non-redundant functions; for TGF-β3, mice with targeted deletion show defects palatogenesis and pulmonary development (2). Human TGF-β3 cDNA encodes a 412 amino acid (aa) precursor that contains a 20 aa signal peptide and a 392 aa proprotein (8). A furin-like convertase processes the proprotein to generate an N-terminal 220 aa latency-associated peptide (LAP) and a C-terminal 112 aa mature TGF-β3 (8, 9). Disulfide-linked homodimers of LAP and TGF-β3 remain non-covalently associated after secretion, forming the small latent TGF-β3 complex (8–10). Covalent linkage of LAP to one of three latent TGF-β binding proteins (LTBPs) creates a large latent complex that may interact with the extracellular matrix (9, 10). TGF-β is activated from latency by pathways that include actions of the protease plasmin, matrix metalloproteases, thrombospondin 1 and a subset of integrins (10). Mature human TGF-β3 shows 100%, 99% and 98% aa identity with mouse/dog/horse, rat and pig TGF-β3, respectively. It demonstrates cross-species activity (1). TGF-β3 signaling begins with high-affinity binding to a type II ser/thr kinase receptor termed TGF-β RII. This receptor then phosphorylates and activates a second ser/thr kinase receptor, TGF-β RI (also called activin receptor-like kinase (ALK) -5), or alternatively, ALK-1. This complex phosphorylates and activates Smad proteins that regulate transcription (3, 11, 12). Contributions of the accessory receptors betaglycan (also known as TGF-β RIII) and endoglin, or use of Smad-independent signaling pathways, allow for disparate actions observed in response to TGF-β in different contexts (11).

References:

1. Sporn, M.B. (2006) Cytokine Growth Factor Rev. **17**:3.
2. Dunker, N. and K. Kriegelstein (2000) Eur. J. Biochem. **267**:6982.
3. Wahl, S.M. (2006) Immunol. Rev. **213**:213.
4. Chang, H. et al. (2002) Endocr. Rev. **23**:787.
5. Lin, J.S. et al. (2006) Reproduction **132**:179.
6. Hinck, A.P. et al. (1996) Biochemistry **35**:8517.
7. Mittl, P.R.E. et al. (1996) Protein Sci. **5**:1261.
8. Derynck, R. et al. (1988) EMBO J. **7**:3737.
9. Miyazono, K. et al. (1988) J. Biol. Chem. **263**:6407.
10. Oklu, R. and R. Hesketh (2000) Biochem. J. **352**:601.
11. de Caestecker, M. et al. (2004) Cytokine Growth Factor Rev. **15**:1.
12. Zuniga, J.E. et al. (2005) J. Mol. Biol. **354**:1052.